Brief: Ipsen, Biomunex Announce Exclusive Global Licensing Agreement For BMX-502

Ipsen SA

03/12/2024 06:05

Dec 3 (Reuters) - Ipsen SA  IPN.PA :

    * IPSEN AND BIOMUNEX ANNOUNCE EXCLUSIVE GLOBAL LICENSING
AGREEMENT
FOR FIRST-IN-CLASS MAIT CELL ENGAGER IN IMMUNO-ONCOLOGY
    * IPSEN TO HANDLE PHASE I PREPARATION AND COMMERCIALIZATION
OF
BMX-502
    * BIOMUNEX ELIGIBLE TO RECEIVE UP TO $610 MLN UNDER
AGREEMENT

Source text:  ID:nGNE4fZv1B 
Further company coverage:  IPN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))